BioLife Solutions Q1 Revenue Jumps 25% to $27.5M, Reaffirms Full-Year Guidance
BLFS sits 29% above its 52-week low of $17.86.
Summary
BioLife Solutions reported strong first-quarter 2026 financial results, with total revenue increasing 25% year-over-year to $27.5 million. The company achieved GAAP net income of $1.2 million and adjusted EBITDA of $6.2 million, marking a significant improvement from an operating loss in the prior year. This positive performance builds on the momentum seen in their 2025 annual report, which detailed strong revenue growth and reduced net losses. The robust demand for its biopreservation media and cell processing tools in the cell and gene therapy market underpins these results. Management also reiterated its full-year 2026 financial guidance, signaling confidence in continued growth and profitability. Traders will be watching for sustained execution against this guidance and further expansion within the dynamic cell and gene therapy landscape.
At the time of this announcement, BLFS was trading at $23.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $17.86 to $29.62. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.